Enterobacteriaceae InfectionsNCT01725841
The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan
An observational study of Enterobacteriaceae Infections, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Resistance to broad-spectrum cephalosporins through the acquisition and expression of Extended-Spectrum β-lactamase (ESBL) among Enterobacteriacea is increasing. The clinical implications of ESBLs are extremely serious and sensitive diagnostic methods are urgently needed to guide therapy, monitor resistance… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Enterobacteriaceae Infections
- How many people
- 300 participants
- Where
- 1 siteTaiwan
- Study dates
- Apr 2009to Sep 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: ENTEROBACTERIACEAE FROM TSAR COLLECTION
Trial locations and contacts
1 site in 1 country.
About this study
Resistance to broad-spectrum cephalosporins through the acquisition and expression of Extended-Spectrum β-lactamase (ESBL) among Enterobacteriacea is increasing. The clinical implications of ESBLs are extremely serious and sensitive diagnostic methods are urgently needed to guide therapy, monitor resistance development and implement intervention strategies. Conventionally, detection of expression of ESBLs was based on reduction of ceftazidime of cefotaxime MICs by ≥ 3 two fold dilutions in the presence of clavulanic acid. However, the use of the above method was limited to cover only some of the bacterial species, including predominantly E. coli and Klebsiella spp., or tested strains which were all transconjugants generated in vitro. ESBLs are now reported in a growing number of genera other than E. coli or Klebsiella spp., and Serratia marcescens.
Carbapenems, including ertapenem, imipenem and meropenem, are the drugs of choice used for severe ESBL-producing bacterial infections. Failure to detect ESBL at the presence of AmpC β-lactamase might result in an important clinical concern because 4th generation cephalosporins, which are stable to AmpC β-lactamase, is not a drug of choice for severe infections caused by ESBLs-producing isolates. Fluoroquinolone-resistance in ESBL-producing Enterobacteriacea is common. In this study, the investigators will use isolates of Enterobacteriacea collected from different hospitals (isolates offered by the Taiwan Surveillance of Antimicrobial Resistance [TSAR] program) to investigate the susceptibility of ertapenem and five other antimicrobial agents against ESBLs-producing Enterobacteriacea.
Read the detailed description
Materials and Methods
- Collection of bacterial isolates The staffs in National Health Research Institute have established a long term surveillance of antimicrobial resistance from 22 to 44 hospitals distributed in all parts of Taiwan-Taiwan Surveillance of Antimicrobial Resistance (TSAR) since 1998. It has been conducted five times in year 1998, 2000, 2002, 2004, and 2006 and were named as TSAR-I, TSAR-II, TSAR-III, TSAR-IV and TSAR-V. In this study, isolates of Enterobacteriaceas from TSAR-IV will be recruited. Each 50 isolates of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens, and Morganella morganii will be enrolled (about 10% of the TSAR IV collected isolates) for the following microbiological studies. Isolates will be divided to ESBL-producing or non-producing groups by screening tests. All the available isolates were identified to the species or genus level by means of conventional methods. Isolates with same species recovered from the same an individual patient, are considered one isolate. The isolates were all stored at -70℃ in trypticase soy broth (Difco Laboratories, Detroit, MI) supplemented with 15% glycerol before being tested.
- Data Collection Information collected for each isolate included: collection date, test date, identification, site of infection, hospital unit of the patient, and whether the isolate was acquired in the community (i.e., specimen obtained <48 hours after admission), the length of patient's hospital stay. The susceptibility of all the isolated against targeted antimicrobial agents will be determined by their Minimum Inhibitory Concentration (MIC values) follow the CLSI breakpoints for respective antimicrobial agent.
- Antimicrobial susceptibility testing
- Inoculums preparation Sterile saline (0.85% NaCl), suitable buffer or broth for inoculums preparation, depending on the organism. The CLSI inoculums procedure for aerobes and other microorganisms should be used. 0.5 McFarland turbidity will be used as the standard for aerobes.
- Inoculation Use sterile loops/swabs to obtain optimal amount of inoculums suspension. Swab the entire agar surface three times; rotating the plate approximately 90 degrees each time to ensure an even distribution of inoculums. Allow excess moisture to be absorbed for about 10-15 minutes so that the surface is completely dry before applying E test strips.
- Application of E test strips Ensure that the inoculated agar surface is completely dry before applying E test strips. Use a Etest applicator or use a forceps to grip the handle of the strip (are labeled E) and place them on to the inoculated agar surface, ensuring that the MIC scale is facing upwards and that the concentration maximum is nearest to the rim of the plate. Make sure the whole strip is in complete contact with the agar surface. Once applied, the strip cannot be moved because of the instantaneous release of antibiotic into the agar. It is recommended to apply 4-6 different E test strips onto a 150 m agar plate. In this study, the E test strips of six antimicrobial agents, including cefepime, cefepime plus clavulanic acid (for the identification of ESBL producing isolates), ciprofloxacin, cefmetazole, amikacin, tigecycline will be applied in addition to ertapenem.
- Incubation The incubation temperature and atmosphere used must be optimal for growth of particular bacterial species and the antibiotic being tested. CLSI recommend 35℃/16-18 hours/ambient atmosphere for non-fastidious aerobes and facultative anaerobes.
- Reading of the MIC After complete the period of incubation and when bacterial growth become distinctly visible, read the MIC value at the point of intersection between the inhibition ellipse edge and the E test strip. Use the E test reading Guide and other technical guides to correctly read different patterns. Etest strip (AB Biodisk, Solna, Sweden) containing cefepime (MIC test range, 0.25-16 mg/L) and cefepime (MIC test range, 0.064-4 mg/L) plus 4 mg/L clavulanic acid will be used to detect the expression of ESBL according to the manufacturer's instruction.reduction of MIC by ≥3 two-fold dilutions in the presence of clavulanic acid is indicator of ESBL production. Deformation of the ellipses or the presence of "phantom" zone is also indicator of ESBL production even if the MIC ratio is <8 or can not be read.
- Quality control In order to check the system with respect to correct handing, quality and consistency of materials and methods, test quality control strains with the antibiotics concerned. S. pneumoniae and H. influenzae can be determined by broth microdilution under ambient incubation. The following organisms are included as control strains: S. aureus ATCC 29213, E. faecalis ATCC 29212, S. pneumoniae ATCC 49619, E. coli ATCC 25922, E. coli ATCC 35218, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853. For every 500 Etests performed, a control test including the above 5 control strains will be done.
- Molecular studies Isolates with expression of ESBLs will be further typed using Pulsed field gel electrophoresis (PFGE) method. The detailed procedures of PFGE and the interpretations of PFGE banding patterns are as the description in our previous report (13).
Data Analysis
Isolates are categorized into susceptible, intermediate, and resistant according to the guidelines provided by the CLSI. Isolates intermediate or resistant to antimicrobial agents are also categorized as nonsusceptible to the agents. The rates of nonsusceptibility among major bacterial pathogens will be analyzed according to the different sites of infection and origin of the isolates. The associations between geographic area, hospital types from whom these isolates were obtained against the antimicrobial susceptibility will be analyzed.
- Conditions
- Enterobacteriaceae Infections
- Keywords
- To determine the prevalence of ESBL-producing among Enterobacteriaceae isolates in Taiwan, To determine the susceptibility of ertapenem and other antimicrobial agents against Enterobacteriaceae isolates with and without expression of ESBLs, To determine the molecular typing of the Enterobacteriaceae isolates with expression of ESBLs, To analyze the association between geographic area, hospital types against the antimicrobial susceptibility
- Medical subject headings
- Enterobacteriaceae Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine the prevalence of ESBL-producing among Enterobacteriaceae isolates in Taiwan
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2012 (estimated)
- Study startApr 2009
- Primary completionAug 2009
- Study completionSep 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Enterobacteriaceae InfectionsStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Retrospective
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shan-Chwen Chang, Ph.D., Principal investigator, Vice President, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01725841
- Sponsor's protocol ID
- 200809012R
- Status last verified
- Nov 2012
- First submitted
- 8 Oct 2009
- Last updated
- 14 Nov 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan
- ClinicalTrials.gov ID
- NCT01725841
- Acronym / sponsor ID
- 200809012R
- Conditions
- Enterobacteriaceae Infections
- Keywords
- To determine the prevalence of ESBL-producing among Enterobacteriaceae isolates in Taiwan, To determine the susceptibility of ertapenem and other antimicrobial agents against Enterobacteriaceae isolates with and without expression of ESBLs, To determine the molecular typing of the Enterobacteriaceae isolates with expression of ESBLs, To analyze the association between geographic area, hospital types against the antimicrobial susceptibility
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Apr 2009
- Primary completion
- Aug 2009 (actual)
- Study completion
- Sep 2009 (actual)
- First posted
- 14 Nov 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Resistance to broad-spectrum cephalosporins through the acquisition and expression of Extended-Spectrum β-lactamase (ESBL) among Enterobacteriacea is increasing. The clinical implications of ESBLs are extremely serious and sensitive diagnostic methods are urgently needed to guide therapy, monitor resistance development and implement intervention strategies. Conventionally, detection of expression of ESBLs was based on reduction of ceftazidime of cefotaxime MICs by ≥ 3 two fold dilutions in the presence of clavulanic acid. However, the use of the above method was limited to cover only some of the bacterial species, including predominantly E. coli and Klebsiella spp., or tested strains which were all transconjugants generated in vitro. ESBLs are now reported in a growing number of genera other than E. coli or Klebsiella spp., and Serratia marcescens.
Carbapenems, including ertapenem, imipenem and meropenem, are the drugs of choice used for severe ESBL-producing bacterial infections. Failure to detect ESBL at the presence of AmpC β-lactamase might result in an important clinical concern because 4th generation cephalosporins, which are stable to AmpC β-lactamase, is not a drug of choice for severe infections caused by ESBLs-producing isolates. Fluoroquinolone-resistance in ESBL-producing Enterobacteriacea is common. In this study, the investigators will use isolates of Enterobacteriacea collected from different hospitals (isolates offered by the Taiwan Surveillance of Antimicrobial Resistance [TSAR] program) to investigate the susceptibility of ertapenem and five other antimicrobial agents against ESBLs-producing Enterobacteriacea.
Detailed description
Materials and Methods
- Collection of bacterial isolates The staffs in National Health Research Institute have established a long term surveillance of antimicrobial resistance from 22 to 44 hospitals distributed in all parts of Taiwan-Taiwan Surveillance of Antimicrobial Resistance (TSAR) since 1998. It has been conducted five times in year 1998, 2000, 2002, 2004, and 2006 and were named as TSAR-I, TSAR-II, TSAR-III, TSAR-IV and TSAR-V. In this study, isolates of Enterobacteriaceas from TSAR-IV will be recruited. Each 50 isolates of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens, and Morganella morganii will be enrolled (about 10% of the TSAR IV collected isolates) for the following microbiological studies. Isolates will be divided to ESBL-producing or non-producing groups by screening tests. All the available isolates were identified to the species or genus level by means of conventional methods. Isolates with same species recovered from the same an individual patient, are considered one isolate. The isolates were all stored at -70℃ in trypticase soy broth (Difco Laboratories, Detroit, MI) supplemented with 15% glycerol before being tested.
- Data Collection Information collected for each isolate included: collection date, test date, identification, site of infection, hospital unit of the patient, and whether the isolate was acquired in the community (i.e., specimen obtained <48 hours after admission), the length of patient's hospital stay. The susceptibility of all the isolated against targeted antimicrobial agents will be determined by their Minimum Inhibitory Concentration (MIC values) follow the CLSI breakpoints for respective antimicrobial agent.
- Antimicrobial susceptibility testing
- Inoculums preparation Sterile saline (0.85% NaCl), suitable buffer or broth for inoculums preparation, depending on the organism. The CLSI inoculums procedure for aerobes and other microorganisms should be used. 0.5 McFarland turbidity will be used as the standard for aerobes.
- Inoculation Use sterile loops/swabs to obtain optimal amount of inoculums suspension. Swab the entire agar surface three times; rotating the plate approximately 90 degrees each time to ensure an even distribution of inoculums. Allow excess moisture to be absorbed for about 10-15 minutes so that the surface is completely dry before applying E test strips.
- Application of E test strips Ensure that the inoculated agar surface is completely dry before applying E test strips. Use a Etest applicator or use a forceps to grip the handle of the strip (are labeled E) and place them on to the inoculated agar surface, ensuring that the MIC scale is facing upwards and that the concentration maximum is nearest to the rim of the plate. Make sure the whole strip is in complete contact with the agar surface. Once applied, the strip cannot be moved because of the instantaneous release of antibiotic into the agar. It is recommended to apply 4-6 different E test strips onto a 150 m agar plate. In this study, the E test strips of six antimicrobial agents, including cefepime, cefepime plus clavulanic acid (for the identification of ESBL producing isolates), ciprofloxacin, cefmetazole, amikacin, tigecycline will be applied in addition to ertapenem.
- Incubation The incubation temperature and atmosphere used must be optimal for growth of particular bacterial species and the antibiotic being tested. CLSI recommend 35℃/16-18 hours/ambient atmosphere for non-fastidious aerobes and facultative anaerobes.
- Reading of the MIC After complete the period of incubation and when bacterial growth become distinctly visible, read the MIC value at the point of intersection between the inhibition ellipse edge and the E test strip. Use the E test reading Guide and other technical guides to correctly read different patterns. Etest strip (AB Biodisk, Solna, Sweden) containing cefepime (MIC test range, 0.25-16 mg/L) and cefepime (MIC test range, 0.064-4 mg/L) plus 4 mg/L clavulanic acid will be used to detect the expression of ESBL according to the manufacturer's instruction.reduction of MIC by ≥3 two-fold dilutions in the presence of clavulanic acid is indicator of ESBL production. Deformation of the ellipses or the presence of "phantom" zone is also indicator of ESBL production even if the MIC ratio is <8 or can not be read.
- Quality control In order to check the system with respect to correct handing, quality and consistency of materials and methods, test quality control strains with the antibiotics concerned. S. pneumoniae and H. influenzae can be determined by broth microdilution under ambient incubation. The following organisms are included as control strains: S. aureus ATCC 29213, E. faecalis ATCC 29212, S. pneumoniae ATCC 49619, E. coli ATCC 25922, E. coli ATCC 35218, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853. For every 500 Etests performed, a control test including the above 5 control strains will be done.
- Molecular studies Isolates with expression of ESBLs will be further typed using Pulsed field gel electrophoresis (PFGE) method. The detailed procedures of PFGE and the interpretations of PFGE banding patterns are as the description in our previous report (13).
Data Analysis
Isolates are categorized into susceptible, intermediate, and resistant according to the guidelines provided by the CLSI. Isolates intermediate or resistant to antimicrobial agents are also categorized as nonsusceptible to the agents. The rates of nonsusceptibility among major bacterial pathogens will be analyzed according to the different sites of infection and origin of the isolates. The associations between geographic area, hospital types from whom these isolates were obtained against the antimicrobial susceptibility will be analyzed.
Study design
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- ENTEROBACTERIACEAE FROM TSAR COLLECTION
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To determine the prevalence of ESBL-producing among Enterobacteriaceae isolates in Taiwan
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2012.
Related trials for Enterobacteriaceae Infections
Not yet recruitingPhase 2
Curcumin Extract Added to Ciprofloxacin for Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program
Typhoid Carrier, Typhoid Fever
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
RecruitingObservational study
Aztreonam-Avibactam in Immunocompromised Hosts
Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection
RecruitingPhase 4
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Blood Stream Infections, Ventilator Associated Pneumonia
RecruitingPhase 2
Cefotetan Therapy for Escherichia Coli Infections
E Coli Infection, ESBL Producing E.Coli
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shan-Chwen Chang, Ph.D. principal investigator
Vice President, National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Enterobacteriaceae Infections, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine the prevalence of ESBL-producing among Enterobacteriaceae isolates in Taiwan (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2012.